We advised CureVac on the equity offering      

Davis Polk advised CureVac N.V. on its $250 million public offering of 27,027,028 common shares. The common shares are listed on the Nasdaq Global Market under the symbol “CVAC.”

CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology with expertise in developing, optimizing and manufacturing this versatile molecule for medical purposes. CureVac is headquartered in Tübingen, Germany, with sites in Germany, the Netherlands, Belgium, Switzerland and the United States.

The Davis Polk corporate team included partner Richard D. Truesdell Jr., counsel Jeffrey S. Ramsay and associates Kamil Turkmani and Carlos E. Romero. The tax team included partner Patrick E. Sigmon and associate Eitan Ulmer. The intellectual property and technology transactions team included partner David R. Bauer and associate Brette L. Trost. Counsel Matthew R. Silver provided 1940 Act advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post